Laboratory Evaluations for Suspected Polycystic Ovary Syndrome (PCOS)

Core Diagnostic Laboratory Tests

The American Academy of Family Physicians recommends comprehensive laboratory testing, including thyroid-stimulating hormone, prolactin, total testosterone or free testosterone, a two-hour oral glucose tolerance test, and fasting lipid profile to properly diagnose PCOS and assess metabolic complications 1, 2, 3
Androgen assessment should measure total testosterone or bioavailable/free testosterone levels, preferably using mass spectrometry for highest accuracy, as recommended by the Human Reproduction Update 4
Thyroid function should be evaluated using thyroid-stimulating hormone (TSH) to rule out thyroid disease as a cause of menstrual irregularity, according to the American Academy of Family Physicians 1, 3
Prolactin level should be measured using morning resting serum levels to exclude hyperprolactinemia, as suggested by the American Academy of Family Physicians and the Journal of Neurology, Neurosurgery and Psychiatry 1, 5
Glucose metabolism should be assessed using a two-hour oral glucose tolerance test with 75g glucose load, as recommended by the American Academy of Family Physicians 1
Lipid profile should include fasting lipid panel with total cholesterol, LDL, HDL, and triglycerides, according to the American Academy of Family Physicians 1, 6

Additional Tests to Consider

Luteinizing hormone (LH) and follicle stimulating hormone (FSH) should be measured between days 3-6 of menstrual cycle, with an LH/FSH ratio >2 suggesting PCOS, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 5
Progesterone levels should be measured in the mid-luteal phase to confirm anovulation, with levels <6 nmol/L indicating anovulation, according to the Journal of Neurology, Neurosurgery and Psychiatry 5
Androstenedione levels should be considered if testosterone levels are normal but clinical suspicion remains high, with levels >10.0 nmol/L indicating adrenal/ovarian tumor, as suggested by the Journal of Neurology, Neurosurgery and Psychiatry 5
DHEAS (Dehydroepiandrosterone sulfate) levels should be measured to rule out non-classical congenital adrenal hyperplasia, especially with elevated levels, according to the Journal of Neurology, Neurosurgery and Psychiatry 5

Metabolic Screening

Glucose/insulin ratio should be measured using fasting morning levels, with a ratio >4 suggesting reduced insulin sensitivity, as recommended by the Journal of Neurology, Neurosurgery and Psychiatry 5
Body mass index (BMI) should be calculated to assess obesity, a common feature of PCOS, according to the American Academy of Family Physicians 6
Waist-hip ratio should be measured to identify central obesity, with a WHR >0.9 indicating truncal obesity, as suggested by the Journal of Neurology, Neurosurgery and Psychiatry 5

Exclusion of Other Conditions

Cushing's syndrome should be screened for if patient has buffalo hump, moon facies, hypertension, abdominal striae, central fat distribution, easy bruising, or proximal myopathies, as recommended by the American Academy of Family Physicians 1, 3
Androgen-secreting tumors should be considered if rapid onset of symptoms, severe hirsutism, or very high testosterone levels, according to the American Academy of Family Physicians 3
Congenital adrenal hyperplasia should be considered if elevated DHEAS levels, as suggested by the Journal of Neurology, Neurosurgery and Psychiatry 5
Acromegaly should be assessed if coarse facial features, enlarged hands/feet are present, according to the American Academy of Family Physicians 3
Primary ovarian failure should be checked using FSH levels, as recommended by the American Academy of Family Physicians 3

Diagnostic Criteria and Laboratory Evaluations for Polycystic Ovary Syndrome (PCOS)

Core Diagnostic Tests and Metabolic Screening

The American Academy of Family Physicians recommends a two-hour oral glucose tolerance test with 75g glucose load to screen for glucose intolerance and type 2 diabetes, and a fasting lipid panel including total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride measurements, as well as calculating body mass index (BMI) to assess obesity and measuring waist-hip ratio to identify central obesity 7
Elevated Anti-Müllerian Hormone (AMH) levels correlate with PCOS diagnosis, with a threshold value of ≥35 pmol/l (5 ng/ml) showing high sensitivity (92%) and specificity (97%) 8
The American Academy of Family Physicians suggests screening for Cushing's Syndrome if the patient has buffalo hump, moon facies, hypertension, abdominal striae, central fat distribution, easy bruising, or proximal myopathies, and considering androgen-secreting tumors if there is rapid onset of symptoms, severe hirsutism, or very high testosterone levels 7
All women with PCOS should be screened for metabolic abnormalities due to the increased risk of type 2 diabetes, dyslipidemia, and cardiovascular disease 7

Ultrasound Criteria for Polycystic Ovarian Morphology

Ultrasound criteria for polycystic ovarian morphology have evolved - using endovaginal ultrasound with 8MHz frequency, the threshold is ≥20 follicles per ovary and/or ovarian volume ≥10ml 8

Laboratory Evaluations for Suspected PCOS

Core Diagnostic Laboratory Tests

Measure total testosterone as the primary androgen marker, which demonstrates a pooled sensitivity of 74% and specificity of 86% for PCOS diagnosis, with LC-MS/MS being the preferred assay method showing superior specificity (92%) compared to direct immunoassays (78%) 9
The diagnostic accuracy of testosterone varies by PCOS diagnostic criteria used—Rotterdam criteria show higher sensitivity (77%) but lower specificity (83%) compared to NIH criteria (sensitivity 51%, specificity 94%) 9

Assay Method Considerations

Direct immunoassays for testosterone have lower specificity (78%) compared to LC-MS/MS (92%), which may lead to false positives 9

Laboratory Diagnosis of Polycystic Ovary Syndrome

First-Line Androgen Testing

The American College of Obstetricians and Gynecologists recommends measuring total testosterone (TT) and free testosterone (FT) as first-line laboratory tests using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for biochemical hyperandrogenism in PCOS diagnosis, with TT showing pooled sensitivity of 74% and specificity of 86%, and FT demonstrating superior sensitivity of 89% with specificity of 83% 10, 11
The 2025 International PCOS Guidelines explicitly recommend TT and FT as first-line tests because they provide the best balance of sensitivity and specificity, with LC-MS/MS being the mandatory preferred assay method, showing superior specificity (92%) compared to direct immunoassays (78%) 10, 11
Calculated free testosterone (cFT) should be assessed by equilibrium dialysis or ammonium sulfate precipitation, or calculated using Free Androgen Index (FAI), with a threshold that can help support PCOS diagnosis 10, 11

Second-Line Androgen Testing

If TT or FT are not elevated but clinical suspicion remains high, androstenedione (A4) can be measured, with sensitivity of 75% and specificity of 71%, and DHEAS can be measured, with sensitivity of 75% and specificity of 67% 11
A4 and DHEAS have poorer specificity than TT/FT and should only be used as adjunctive tests, according to the International PCOS Guidelines 10, 11

Diagnostic Algorithm

The diagnostic algorithm recommends measuring TT and FT using LC-MS/MS as the first step, with a calculated Free Androgen Index (FAI) as an alternative if LC-MS/MS is unavailable 10, 11
If TT/FT normal but clinical suspicion high, the algorithm suggests measuring A4 and DHEAS as the next step 10, 11

PCOS Diagnosis and Laboratory Findings

Diagnostic Criteria

The American Society for Reproductive Medicine recommends that a woman can be diagnosed with PCOS based solely on clinical hyperandrogenism (hirsutism, acne, or alopecia) plus irregular menstrual cycles, without any abnormal laboratory values, as stated in the Rotterdam criteria, which requires only two of three features to diagnose PCOS: oligo- or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound 12

Laboratory Testing

Total testosterone is abnormal in only 70% of women with confirmed PCOS, meaning 30% have normal testosterone levels despite having the condition, and the LH/FSH ratio >2 is abnormal in only 35-44% of women with PCOS, making it a poor diagnostic marker 12
The presence of ≥20 follicles per ovary and/or ovarian volume ≥10mL on ultrasound confirms polycystic ovarian morphology, and when clinical features and ultrasound findings are present, the absence of biochemical hyperandrogenism does not exclude PCOS 13

Clinical Assessment

The Endocrine Society suggests that clinical assessment, including menstrual pattern, physical signs of hyperandrogenism, and ultrasound morphology, remains paramount and can establish the diagnosis even when all laboratory tests return normal 12, 13

Diagnostic du Syndrome des Ovaire Polykystiques (SOPK)

Évaluation de l'Hormone Anti-Müllérienne (AMH)

L'American College of Endocrinology suggère que l'AMH ne devrait pas être utilisée comme alternative pour détecter la morphologie ovarienne polykystique ou comme test unique pour le diagnostic du SOPK, car des valeurs seuils d'AMH ≥35 pmol/L (5 ng/mL) montrent une sensibilité élevée (92%) et une spécificité (97%), mais nécessitent une validation supplémentaire dans différentes populations 14
L'AMH est un substitut potentiel futur pour détecter la morphologie ovarienne polykystique, mais des recherches supplémentaires sont nécessaires, avec une sensibilité élevée et une spécificité élevée, mais qui nécessitent une validation supplémentaire 14

Laboratory Testing for PCOS and Fertility

Essential First-Line Hormonal Tests

The American College of Obstetricians and Gynecologists recommends measuring progesterone during the mid-luteal phase to confirm anovulation, with levels <6 nmol/L indicating anovulation, in women with PCOS seeking fertility 15
Measuring thyroid-stimulating hormone (TSH) is crucial to rule out thyroid disease as a cause of menstrual irregularity and infertility in women with PCOS 15
Measuring prolactin using morning resting serum levels is essential to exclude hyperprolactinemia, with levels >20 μg/L considered abnormal, in women with PCOS 15

Additional Hormonal Tests to Consider

Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) should be measured between days 3-6 of the menstrual cycle, calculating based on an average of three estimations taken 20 minutes apart, to assess hormonal imbalance in women with PCOS 15
An LH/FSH ratio >2 suggests PCOS, though this is abnormal in only 35-44% of women with PCOS, making it a poor standalone diagnostic marker 15

Mandatory Metabolic Screening

Measuring fasting glucose and insulin levels, with a glucose/insulin ratio >4, suggests reduced insulin sensitivity in women with PCOS 15
Calculating body mass index (BMI), with BMI >25 considered obese, is essential to assess cardiovascular risk in women with PCOS 15
Measuring waist-hip ratio (WHR) to identify central obesity, with WHR >0.9 indicating truncal obesity, is crucial to assess metabolic risk in women with PCOS 15

PCOS Diagnosis and Interpretation

Diagnostic Criteria

The American College of Obstetricians and Gynecologists recommends using the Rotterdam criteria, which have a sensitivity of 77-89% and specificity of 83%, to diagnose PCOS, as studies have shown higher sensitivity but lower specificity compared to NIH criteria 16, 17
The Rotterdam criteria require the presence of at least two of three criteria: oligo/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound, with a sensitivity of 87.64% and specificity of 93.74% for follicle number per ovary ≥20 follicles 16, 17
Ovarian volume >10 mL serves as an alternative criterion with 81.48% sensitivity and 81.04% specificity, and follicle number per single cross-section is a secondary alternative marker with 81.07% sensitivity and 82.70% specificity 16, 17

Ultrasound Assessment

The American Institute of Ultrasound in Medicine recommends using transvaginal ultrasound with ≥8 MHz transducer frequency for optimal resolution in adults 17
In adolescents, ovarian volume shows 81.84% sensitivity and 83.54% specificity, but ultrasound should be avoided as a first-line diagnostic tool due to poor specificity and high false-positive rates 17

Biomarkers

Anti-Müllerian hormone (AMH) ≥35 pmol/L shows 92% sensitivity and 97% specificity, but should not replace ultrasound or serve as a standalone diagnostic test due to lack of assay standardization 18

Diagnostic Considerations for PCOS

Critical Diagnostic Considerations

If the patient has both irregular menstrual cycles AND clinical/biochemical hyperandrogenism, ultrasound is not necessary for PCOS diagnosis, though it will identify the complete PCOS phenotype, as recommended by the Endocrine Society 19, 20, 21
Do not use AMH levels as an alternative for detecting polycystic ovarian morphology or as a single test for PCOS diagnosis due to lack of standardization, no validated cut-offs, and significant overlap between women with and without PCOS, according to the Endocrine Society 19, 20, 21
Ultrasound should not be used for PCOS diagnosis in those with gynecological age <8 years (<8 years after menarche) due to high incidence of multifollicular ovaries in this life stage, as suggested by the Endocrine Society 19, 20, 21

Diagnostic Criteria and Metabolic Screening for PCOS

Core Diagnostic Laboratory Tests and Metabolic Screening

The American College of Obstetricians and Gynecologists and Endocrine Society recommend ordering a fasting lipid panel including total cholesterol, LDL, HDL, and triglycerides to assess dyslipidemia driven by insulin resistance, with target LDL <100 mg/dL, HDL >35 mg/dL, and triglycerides <150 mg/dL 22
The American College of Cardiology recommends monitoring cardiovascular risk factors every 6-12 months, including weight changes and blood pressure 23

PCOS Diagnosis and Management

Diagnostic Criteria and Laboratory Tests

Central obesity exacerbates metabolic, reproductive, and psychological features of PCOS, as indicated by a waist-hip ratio >0.9, according to Obesity Reviews 24, 25
The American College of Endocrinology recommends confirming prolactin elevation with 2-3 samples at 20-60 minute intervals via indwelling cannula to exclude stress-related spurious elevation, in the diagnosis of PCOS 24, 25

Metabolic Screening and Lifestyle Intervention

Obesity prevalence in PCOS has increased from 51% in the 1990s to 74% in recent decades, highlighting the need for weight assessment and lifestyle intervention, as reported by Obesity Reviews 24
Weight gain escalates from adolescence, requiring early vigilance, and central obesity exacerbates metabolic, reproductive, and psychological features of PCOS, according to Obesity Reviews 25

Hormone Levels in PCOS Patients

Introduction to Hormone Patterns

During GnRH stimulation testing, PCOS women demonstrate stimulated LH levels of approximately 35.48 ± 31.4 IU/L 26
FSH levels are typically normal or low-normal in PCOS patients, and estradiol levels are usually within normal range but may be tonically elevated 27
SHBG is typically decreased in PCOS patients, particularly those with higher LH levels, and AMH levels increase progressively with higher LH:FSH ratios 27

Hormonal and Metabolic Evaluation in Polycystic Ovary Syndrome (PCOS)

First‑Line Androgen Assessment

Measure total testosterone and free testosterone by liquid chromatography‑tandem mass spectrometry (LC‑MS/MS); total testosterone shows ~74 % sensitivity and 86 % specificity, while free testosterone shows ~89 % sensitivity and 83 % specificity for detecting hyperandrogenism in women with PCOS. 28
LC‑MS/MS assays provide superior analytical specificity (~92 %) compared with direct immunoassays (~78 %), which have a high false‑positive rate for androgen measurement. 28

Thyroid and Prolactin Screening

Obtain a serum thyroid‑stimulating hormone (TSH) level to exclude thyroid disease as a cause of menstrual irregularity. 29
Measure morning resting serum prolactin; values >20 µg/L are considered abnormal and warrant further evaluation for hyperprolactinemia. 29

Second‑Line Androgen Tests (when primary androgen results are normal)

Assess serum androstenedione; values >10 nmol/L raise suspicion for an adrenal or ovarian androgen‑secreting tumor. 29
Assess serum DHEAS; age‑adjusted thresholds (≥3800 ng/mL for ages 20‑29, ≥2700 ng/mL for ages 30‑39) should prompt evaluation for non‑classical congenital adrenal hyperplasia. 29

Ovulatory Function Evaluation

Measure luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) on cycle days 3‑6 (if cycles occur), averaging three samples taken 20 minutes apart; an LH/FSH ratio >2 supports PCOS but is present in only ~35‑44 % of affected women, limiting its diagnostic utility. 29
Determine mid‑luteal phase progesterone; concentrations <6 nmol/L indicate anovulation. 29

Metabolic Screening in PCOS

Perform a 2‑hour oral glucose tolerance test with a 75 g glucose load; fasting glucose >7.8 mmol/L suggests diabetes. 29
Measure fasting glucose and insulin; a glucose/insulin ratio >4 is indicative of reduced insulin sensitivity. 29
Calculate body‑mass index (BMI) and waist‑hip ratio (WHR); a WHR >0.9 denotes truncal obesity and heightened metabolic risk. 29

Anti‑Müllerian Hormone (AMH) Guidance

Do not use AMH as a stand‑alone test for polycystic ovarian morphology or PCOS diagnosis because of lack of assay standardisation, absent validated cut‑offs, and considerable overlap between affected and unaffected women. 30
Although an AMH level ≥35 pmol/L has shown 92 % sensitivity and 97 % specificity for PCOS in research cohorts, this threshold requires further validation across diverse populations before clinical adoption. 30

Essential Exclusions and Diagnostic Pitfalls in PCOS Evaluation

Hormonal and Endocrine Conditions to Exclude

Ultrasound Morphology Considerations

Diagnostic Criteria Framework

Recommendations Against Routine Insulin and C‑Peptide Testing in PCOS Evaluation

Laboratory Testing Recommendations

The American College of Obstetricians and Gynecologists advises that insulin and C‑peptide should not be measured routinely in women being evaluated for suspected polycystic ovary syndrome; physical signs of insulin resistance (e.g., elevated body mass index, acanthosis nigricans) are deemed sufficient for assessment. 33

Diagnosis and Management of Anovulatory Polycystic Ovary Syndrome (PCOS)

Diagnostic Criteria

A mid‑cycle progesterone level < 6 nmol/L (≈ 0.2 ng/mL) confirms anovulation and indicates follicular arrest without corpus luteum formation; measurement should be performed 7 days before the expected menses (day 21 of a 28‑day cycle or day 14 of an irregular cycle)【34】.
Elevated free testosterone with normal total testosterone and low SHBG is a characteristic hormonal pattern of PCOS【34】.
A morning resting prolactin level > 20 µg/L is abnormal and should be excluded when evaluating hyperandrogenism【34】.
DHEAS > 3800 ng/mL in women aged 20‑29 suggests non‑classical congenital adrenal hyperplasia and warrants further assessment【34】.

Metabolic Assessment

All women with PCOS should undergo metabolic screening regardless of fertility intentions【35】.
Screen for glucose intolerance with a 2‑hour oral glucose tolerance test (75 g glucose load)【35】.
Perform a fasting lipid panel; PCOS patients frequently exhibit elevated LDL, reduced HDL, and increased triglycerides【35】.
Calculate BMI and assess central obesity (waist‑hip ratio > 0.9); weight loss of 5‑10 % improves ovulation rates in overweight/obese individuals【35】.

Management When Fertility Is Desired

Lifestyle modification (weight loss 5‑10 %) is first‑line and significantly enhances ovulation frequency【35】.
Ovulation induction: Letrozole or clomiphene citrate are recommended first‑line agents for PCOS‑related anovulatory infertility【35】.
Metformin may be added to improve insulin sensitivity and augment ovulation rates【35】.
Metformin also improves metabolic outcomes, decreases circulating androgens, and tends to promote modest weight loss【35】.

Management When Fertility Is Not Desired

Combined oral contraceptive pills (OCPs) are first‑line to suppress ovarian androgen production, raise SHBG, reduce free testosterone, improve hirsutism, and provide endometrial protection【35】.
OCP use reduces the risk of endometrial cancer associated with chronic unopposed estrogen exposure【35】.
Metformin can be employed to improve insulin sensitivity and metabolic parameters, even when pregnancy is not sought【35】.

Critical Pitfalls

Clomiphene citrate should not be used in functional hypothalamic amenorrhea (FHA) because it is ineffective and not recommended【36】【37】.
The presence of hyperandrogenism (elevated free testosterone, hirsutism) helps differentiate PCOS from FHA, which typically shows low gonadotropins and no hyperandrogenism【36】【37】.

Long‑Term Monitoring

Conduct lipid panel, blood pressure, and weight assessments every 6–12 months【35】.
Recognize the increased lifelong risk of type 2 diabetes, dyslipidemia, and cardiovascular disease in women with PCOS【35】.

Role of TSH Screening in Differentiating Hypothalamic Amenorrhea from PCOS in Women with Ovarian Cysts

Differential Diagnosis of Ovarian Cysts

In reproductive‑age women presenting with ovarian cysts, measuring serum TSH is essential because hypothalamic amenorrhea—characterized by low luteinizing hormone and absence of hyperandrogenism—can mimic polycystic ovarian morphology in 17–22 % of cases, necessitating distinction from true PCOS for appropriate management. 38

Management and Monitoring of Polycystic Ovary Syndrome (PCOS)

Diagnostic Biomarkers

Elevated serum DHEA‑Sulfate (approximately 650 µg/dL) serves as a useful biochemical marker for PCOS, demonstrating about 75 % sensitivity and 67 % specificity for the disorder. 39

Metabolic Assessment and Risk Stratification

A hemoglobin A1c at the upper limit of normal (≈5.5 %) identifies pre‑diabetic status in women with PCOS and justifies immediate, intensive lifestyle modification to prevent progression to type 2 diabetes. 40
Even when baseline lipid values are within normal ranges, women with PCOS require annual lipid profiling because the condition confers a disproportionately high cardiovascular risk. 40
The chronic anovulation, obesity, and hyperinsulinemia associated with PCOS markedly increase the risk of endometrial hyperplasia and carcinoma; therefore, endometrial protection is a key therapeutic goal. 40
Long‑term surveillance should include periodic 2‑hour oral glucose tolerance testing to detect conversion to overt diabetes and fasting lipid panels to monitor evolving dyslipidemia. 40
PCOS is linked to a lifelong heightened risk of type 2 diabetes, metabolic syndrome, non‑alcoholic fatty liver disease, hypertension, dyslipidemia, and cardiovascular disease. 40

First‑Line Pharmacologic Therapy

Combined oral contraceptive pills (COCs) are recommended as first‑line treatment for menstrual irregularities, hirsutism, and endometrial protection in PCOS; they suppress ovarian androgen production, raise sex‑hormone‑binding globulin, regularize cycles, and lower the risk of endometrial hyperplasia. 41
Metformin (starting at 850 mg three times daily and titrated as tolerated) should be added to address insulin resistance, improve glucose tolerance, lower circulating androgens, modestly promote weight loss, and enhance menstrual regularity, especially in patients with pre‑diabetic glycemic indices. [41][40]

Lifestyle Intervention

A structured, multicomponent lifestyle program—including dietary modification, regular aerobic and resistance exercise, and behavioral counseling—is essential for all women with PCOS, irrespective of body‑mass index, because insulin resistance can exist independent of obesity. 41
Achieving as little as a 5 % reduction in body weight can significantly improve both metabolic parameters (e.g., insulin sensitivity) and reproductive outcomes (e.g., ovulatory frequency). 41
Even in the absence of weight loss, consistent physical activity yields favorable metabolic effects such as improved insulin sensitivity and lipid profiles. 41

Hirsutism Management

The combination of a COC plus an anti‑androgen (e.g., spironolactone) is the most effective medical regimen for reducing hirsutism in PCOS; spironolactone may be introduced after 3–6 months if hirsutism persists despite COC therapy. 41
Mechanical hair‑removal techniques (laser, electrolysis) can be used as adjuncts but do not address the underlying androgen excess and therefore should be combined with medical therapy. 41

Ongoing Monitoring and Surveillance (Every 6–12 Months)

Oral glucose tolerance test (75 g) to screen for progression to type 2 diabetes. 40
Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) to track cardiovascular risk. 40
Blood pressure measurement to detect emerging hypertension.
Body weight and BMI assessment to evaluate response to lifestyle and pharmacologic interventions.

Long‑Term Health Implications and Preventive Counseling

Early and sustained intervention with lifestyle modification, COCs, and metformin can markedly reduce the long‑term risks of diabetes, metabolic syndrome, cardiovascular disease, and endometrial pathology, while also improving reproductive health. 41